Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers With Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial

Journal of Biomedicine and Biotechnology
doi 10.1155/2011/185646
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2015English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2008English

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2011English

Gemcitabine Plus Vinorelbine as First-Line Chemotherapy in Advanced Nonsmall Cell Lung Carcinoma a Phase II Trial

Cancer
Cancer ResearchOncology
2000English

Phase II Trial of Sequential Gefitinib After Minor Response or Partial Response to Chemotherapy in Chinese Patients With Advanced Non-Small-Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus

Cancer
Cancer ResearchOncology
2010English

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2008English

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

International Journal of Cancer
Cancer ResearchOncology
2017English

Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial

The Lancet
Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy